Index RUT P/E - EPS (ttm) -3.29 Insider Own 48.70% Shs Outstand 47.67M Perf Week 14.45%
Market Cap 787.56M Forward P/E - EPS next Y -3.14 Insider Trans -0.59% Shs Float 25.51M Perf Month 33.56%
Income -143.51M PEG - EPS next Q -0.78 Inst Own 32.17% Short Float 2.27% Perf Quarter 3.33%
Sales 0.00M P/S - EPS this Y 0.07% Inst Trans -0.53% Short Ratio 3.85 Perf Half Y 12.18%
Book/sh 4.87 P/B 3.25 EPS next Y -3.23% ROA -46.66% Short Interest 0.58M Perf Year 7.68%
Cash/sh 5.49 P/C 2.89 EPS next 5Y - ROE -59.55% 52W Range 9.94 - 20.22 Perf YTD -1.31%
Dividend Est. - P/FCF - EPS past 5Y -241.80% ROI -50.05% 52W High -21.66% Beta 0.88
Dividend TTM - Quick Ratio 10.92 Sales past 5Y 0.00% Gross Margin - 52W Low 59.36% ATR (14) 0.94
Dividend Ex-Date - Current Ratio 10.92 EPS Y/Y TTM 12.39% Oper. Margin 0.00% RSI (14) 63.15 Volatility 8.97% 6.42%
Employees 90 Debt/Eq 0.21 Sales Y/Y TTM - Profit Margin - Recom 1.00 Target Price 29.60
Option/Short No / Yes LT Debt/Eq 0.20 EPS Q/Q -35.68% Payout - Rel Volume 0.75 Prev Close 15.57
Sales Surprise - EPS Surprise -19.02% Sales Q/Q - Earnings May 09 AMC Avg Volume 150.31K Price 15.84
SMA20 17.51% SMA50 6.43% SMA200 11.35% Trades
Volume 112,735 Change 1.73%
Date
Action
Analyst
Rating Change
Price Target Change
Dec-13-23 Initiated H.C. Wainwright
Buy
$28
May-10-24 02:26PM
May-09-24 11:55PM
04:05PM
Apr-14-24 12:52PM
Apr-06-24 01:33AM
02:32AM
Loading…
Mar-21-24 02:32AM
Mar-20-24 09:53PM
04:00PM
Mar-08-24 11:55PM
Feb-22-24 11:27PM
Feb-05-24 04:05PM
Jan-18-24 07:00AM
Jan-08-24 07:00AM
Jan-03-24 06:28PM
Dec-19-23 01:01PM
09:48PM
Loading…
Dec-05-23 09:48PM
Nov-30-23 09:55AM
Nov-21-23 11:03AM
Nov-14-23 12:00PM
09:55AM
Nov-09-23 04:05PM
Nov-01-23 04:48PM
Sep-26-23 04:01PM
Sep-25-23 07:00AM
Sep-19-23 08:05PM
04:09PM
Aug-24-23 10:40AM
Aug-14-23 05:08PM
(American City Business Journals) -7.26%
07:00AM
Jun-07-23 09:55AM
09:55AM
Loading…
May-22-23 09:55AM
May-12-23 04:05PM
May-09-23 07:00AM
Apr-25-23 06:45AM
HilleVax, Inc. is a clinical-stage biopharmaceutical company, which focuses on developing and commercializing novel vaccines. Its pipeline includes Norovirus and HIL-214. The company was founded by Maurice Hilleman and Tadataka Yamada on March 25, 2020 and is headquartered in Boston, MA.
Insider Trading
Relationship
Date
Transaction
Cost
#Shares
Value ($)
#Shares Total
SEC Form 4
Kohli Aditya Director May 03 '24 Sale 14.15 723 10,233 782,878 May 03 07:12 PM Kohli Aditya Director May 02 '24 Sale 14.01 6,000 84,081 783,601 May 03 07:12 PM Kohli Aditya Director May 01 '24 Sale 14.03 175 2,456 789,601 May 03 07:12 PM Kohli Aditya Director Apr 05 '24 Sale 14.44 6,000 86,640 789,776 Apr 05 05:48 PM Frazier Life Sciences X, L.P. 10% Owner Apr 04 '24 Buy 14.50 8,850 128,325 8,544,187 Apr 08 04:22 PM Kohli Aditya Director Apr 04 '24 Sale 14.71 6,000 88,245 795,776 Apr 05 05:48 PM Kohli Aditya Director Apr 03 '24 Sale 14.93 6,000 89,582 801,776 Apr 05 05:48 PM McLoughlin Sean Chief Operating Officer Mar 28 '24 Buy 16.98 1,250 21,225 1,250 Apr 01 04:08 PM Kohli Aditya Director Mar 20 '24 Sale 16.42 6,000 98,533 807,776 Mar 20 06:27 PM Kohli Aditya Director Mar 19 '24 Sale 17.42 6,000 104,492 813,776 Mar 20 06:27 PM Kohli Aditya Director Mar 18 '24 Sale 17.66 6,000 105,937 819,776 Mar 20 06:27 PM Kohli Aditya Director Mar 08 '24 Sale 18.66 6,000 111,959 825,776 Mar 08 06:38 PM Kohli Aditya Director Mar 07 '24 Sale 18.37 6,000 110,213 831,776 Mar 08 06:38 PM Kohli Aditya Director Mar 06 '24 Sale 18.95 6,000 113,701 837,776 Mar 08 06:38 PM Kohli Aditya Director Feb 22 '24 Sale 15.05 6,000 90,312 843,776 Feb 22 05:20 PM Kohli Aditya Director Feb 21 '24 Sale 14.92 6,000 89,495 849,776 Feb 22 05:20 PM Kohli Aditya Director Feb 20 '24 Sale 14.88 6,000 89,272 855,776 Feb 22 05:20 PM Kohli Aditya Director Feb 12 '24 Sale 15.32 6,000 91,921 861,776 Feb 14 04:22 PM HERSHBERG ROBERT See Remarks Feb 08 '24 Sale 14.93 11,597 173,161 953,831 Feb 12 07:47 PM Kohli Aditya Director Feb 08 '24 Sale 14.93 8,866 132,383 812,878 Feb 12 08:06 PM Borkowski Astrid Chief Medical Officer Feb 08 '24 Sale 14.93 3,933 58,726 161,260 Feb 12 07:35 PM Maltbie Shane Chief Financial Officer Feb 08 '24 Sale 14.93 3,576 53,395 40,656 Feb 12 07:51 PM Borkowski Astrid Chief Medical Officer Dec 15 '23 Sale 15.50 10,000 155,000 165,193 Dec 18 05:34 PM Borkowski Astrid Chief Medical Officer Dec 04 '23 Sale 14.50 10,000 145,000 175,193 Dec 05 04:52 PM Borkowski Astrid Chief Medical Officer Dec 01 '23 Sale 14.20 10,000 142,000 185,193 Dec 05 04:52 PM Borkowski Astrid Chief Medical Officer Nov 17 '23 Sale 14.00 10,000 140,000 195,193 Nov 20 04:53 PM Borkowski Astrid Chief Medical Officer Nov 08 '23 Sale 13.00 5,000 65,000 205,193 Nov 13 05:25 PM
Index RUT P/E - EPS (ttm) -1.92 Insider Own 12.24% Shs Outstand 113.83M Perf Week -4.41%
Market Cap 443.94M Forward P/E - EPS next Y -1.85 Insider Trans -0.07% Shs Float 99.89M Perf Month -22.62%
Income -190.05M PEG - EPS next Q -0.46 Inst Own 95.58% Short Float 22.16% Perf Quarter -48.41%
Sales 6.48M P/S 68.51 EPS this Y -14.49% Inst Trans -2.86% Short Ratio 8.33 Perf Half Y 57.26%
Book/sh 3.74 P/B 1.04 EPS next Y 1.21% ROA -31.67% Short Interest 22.14M Perf Year -22.47%
Cash/sh 3.37 P/C 1.16 EPS next 5Y - ROE -42.07% 52W Range 1.63 - 8.83 Perf YTD 4.28%
Dividend Est. - P/FCF - EPS past 5Y -6.65% ROI -36.42% 52W High -55.83% Beta 1.93
Dividend TTM - Quick Ratio 8.69 Sales past 5Y 87.14% Gross Margin -191.94% 52W Low 139.26% ATR (14) 0.40
Dividend Ex-Date - Current Ratio 8.69 EPS Y/Y TTM 20.82% Oper. Margin -3287.85% RSI (14) 34.28 Volatility 10.16% 9.10%
Employees 181 Debt/Eq 0.24 Sales Y/Y TTM -95.27% Profit Margin -2933.79% Recom 2.50 Target Price 6.81
Option/Short Yes / Yes LT Debt/Eq 0.22 EPS Q/Q -146.52% Payout - Rel Volume 0.50 Prev Close 4.14
Sales Surprise 15.94% EPS Surprise 0.38% Sales Q/Q -96.74% Earnings May 09 AMC Avg Volume 2.66M Price 3.90
SMA20 -5.85% SMA50 -32.46% SMA200 -3.68% Trades
Volume 1,339,475 Change -5.80%
Date
Action
Analyst
Rating Change
Price Target Change
Mar-27-23 Resumed Wells Fargo
Equal Weight
$6
Jan-24-23 Downgrade H.C. Wainwright
Buy → Neutral
$115 → $7
Jan-06-23 Downgrade Wedbush
Outperform → Neutral
$42 → $7
Jan-06-23 Downgrade Truist
Buy → Hold
$46 → $7
Jan-06-23 Downgrade Stifel
Buy → Hold
$107 → $5.30
Jan-06-23 Downgrade Piper Sandler
Overweight → Neutral
$71 → $12
Jan-06-23 Downgrade Cowen
Outperform → Market Perform
Jan-06-23 Downgrade BofA Securities
Buy → Underperform
$72 → $4
Jan-06-23 Downgrade BMO Capital Markets
Outperform → Market Perform
$20 → $7
Jan-03-23 Downgrade Guggenheim
Buy → Neutral
Dec-22-22 Downgrade Oppenheimer
Outperform → Perform
Dec-15-22 Initiated Goldman
Sell
$10
Nov-04-22 Resumed Cantor Fitzgerald
Overweight
$98 → $45
Oct-10-22 Initiated Canaccord Genuity
Buy
$42
Aug-18-22 Resumed Wells Fargo
Overweight
$90
Jul-28-22 Initiated Needham
Hold
Jul-11-22 Upgrade BMO Capital Markets
Market Perform → Outperform
$50 → $47
Jun-03-22 Initiated Robert W. Baird
Neutral
$28
Feb-11-22 Resumed BMO Capital Markets
Market Perform
$50
Dec-15-21 Upgrade Wedbush
Neutral → Outperform
Show Previous Ratings
May-13-24 10:48AM
May-10-24 02:50PM
10:36AM
08:22AM
May-09-24 08:58PM
05:25PM
Loading…
05:25PM
04:21PM
(Associated Press Finance)
04:01PM
08:30AM
May-06-24 08:00AM
May-03-24 04:30PM
Apr-22-24 04:30PM
Apr-06-24 02:17AM
Apr-04-24 11:30PM
Apr-03-24 08:00AM
04:01PM
Loading…
Apr-02-24 04:01PM
Mar-27-24 11:30AM
Mar-19-24 08:44AM
Mar-05-24 04:01PM
Mar-01-24 08:09AM
08:00AM
Feb-27-24 09:16AM
08:07AM
(Thomson Reuters StreetEvents)
Feb-26-24 05:10PM
04:35PM
04:08PM
(Associated Press Finance)
04:01PM
Feb-21-24 09:21AM
Feb-19-24 10:00AM
Feb-15-24 08:00AM
04:01PM
Loading…
Feb-02-24 04:01PM
Jan-30-24 07:54AM
Jan-29-24 02:53PM
Jan-08-24 08:00AM
Dec-22-23 12:00PM
Dec-18-23 02:58PM
Dec-13-23 05:00PM
Dec-08-23 11:30AM
Nov-09-23 01:18PM
Nov-08-23 06:18PM
04:08PM
(Associated Press Finance)
04:01PM
Oct-25-23 08:00AM
Sep-15-23 06:01AM
Sep-07-23 11:30AM
Aug-31-23 08:00AM
Aug-29-23 07:30AM
Aug-09-23 12:12PM
11:04AM
(Thomson Reuters StreetEvents)
Aug-08-23 05:15PM
04:11PM
(Associated Press Finance)
04:01PM
Jul-28-23 08:00AM
Jul-22-23 08:35AM
Jul-01-23 10:33AM
Jun-16-23 03:53PM
Jun-14-23 06:42AM
Jun-08-23 11:30AM
Jun-07-23 11:30AM
Jun-04-23 08:27AM
Jun-02-23 11:31AM
May-31-23 08:00AM
May-25-23 10:49AM
May-08-23 06:05AM
May-04-23 11:59AM
11:22AM
(Thomson Reuters StreetEvents)
May-03-23 05:15PM
04:11PM
04:01PM
12:00PM
Apr-27-23 10:03AM
Apr-26-23 10:02AM
Apr-24-23 08:00AM
Apr-12-23 07:20AM
Mar-30-23 11:30AM
Mar-27-23 09:00AM
Mar-03-23 04:01PM
Mar-02-23 09:18PM
05:30AM
Mar-01-23 09:59AM
Feb-28-23 05:15PM
04:01PM
Feb-27-23 09:31AM
Feb-13-23 08:00AM
Feb-06-23 09:55AM
Feb-02-23 09:46AM
Jan-30-23 07:33AM
Jan-28-23 01:30PM
Jan-19-23 09:35AM
Jan-17-23 06:27AM
Jan-06-23 01:55PM
10:54AM
10:27AM
08:49AM
Jan-05-23 05:00PM
07:40AM
Jan-03-23 09:35AM
Jan-02-23 08:39AM
Dec-13-22 08:00AM
Dec-12-22 07:30AM
Fate Therapeutics, Inc. engages in the development of programmed cellular immunotherapies for cancer and immune disorder. Its pipeline of products includes immuno-ocology candidates and immuno-regulation candidates. The company was founded by Philip Beachy, Sheng Ding, Rudolf Jaenisch, Randall T. Moon, Michael Rudnicki, David Scadden, Leonard Zon, Alexander Rives, Scott Wolchko, and John D. Mendlein on April 27, 2007 and is headquartered in San Diego, CA.
Insider Trading
Relationship
Date
Transaction
Cost
#Shares
Value ($)
#Shares Total
SEC Form 4
Dulac Edward J III Chief Financial Officer Mar 04 '24 Sale 7.77 2,447 19,013 101,479 Mar 05 04:24 PM Dulac Edward J III Chief Financial Officer Jan 29 '24 Sale 5.00 1,849 9,245 103,926 Jan 30 04:01 PM Wolchko J Scott President and CEO Jan 09 '24 Sale 4.37 14,391 62,889 371,248 Jan 10 04:29 PM Valamehr Bahram Chief R&D Officer Jan 09 '24 Sale 4.38 11,271 49,367 158,069 Jan 10 04:30 PM TAHL CINDY General Counsel and Secretary Jan 09 '24 Sale 4.37 10,874 47,519 142,361 Jan 10 04:30 PM Dulac Edward J III Chief Financial Officer Jan 09 '24 Sale 4.37 7,028 30,712 105,775 Jan 10 04:29 PM Dulac Edward J III Chief Financial Officer Jan 02 '24 Sale 3.66 5,182 18,966 112,803 Jan 03 04:03 PM Redmile Group, LLC Director Dec 26 '23 Buy 3.72 44,630 166,024 13,180,388 Dec 28 09:30 PM Dulac Edward J III Chief Financial Officer Dec 18 '23 Sale 3.50 1,585 5,548 117,985 Dec 19 04:01 PM TAHL CINDY General Counsel and Secretary Nov 09 '23 Sale 2.40 24,363 58,471 153,235 Nov 13 04:01 PM Dulac Edward J III Chief Financial Officer Aug 18 '23 Sale 2.80 4,718 13,210 119,570 Aug 21 04:02 PM Xu Yuan Director Aug 04 '23 Sale 3.71 632 2,345 9,302 Aug 07 04:01 PM Dulac Edward J III Chief Financial Officer Jul 05 '23 Sale 4.83 5,182 25,029 124,288 Jul 06 05:18 PM Powl Brian T. Chief Commercial Officer Jul 05 '23 Sale 4.87 3,854 18,769 41,146 Jul 06 05:19 PM Xu Yuan Director Jun 14 '23 Sale 5.58 3,460 19,307 9,934 Jun 15 04:05 PM
×
Upgrade your FINVIZ experience
Join thousands of traders who make more informed decisions with our premium features.
Real-time quotes, advanced visualizations, backtesting, and much more.
Learn more about FINVIZ*Elite
